News APP

NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  gplay

This article was first published 5 years ago
Home  » Sports » Semenya files appeal to Swiss supreme court

Semenya files appeal to Swiss supreme court

May 29, 2019 23:59 IST
Get Rediff News in your Inbox:

'I am a woman and I am a world-class athlete. The IAAF will not drug me or stop me from being who I am.'

Caster Semeny

IMAGE: Caster Semenya will ask the Swiss Federal Supreme Court to set aside CAS's decision in its entirety, which it said did not consider medical protocols and uncertain health consequences of taking testosterone-reducing medication. Photograph: Francois Nel/Getty Images

Olympic 800 metres champion Caster Semenya has filed an appeal to Switzerland's highest court against a ruling to uphold rules requiring that middle-distance female athletes with a high natural level of testosterone must take medication to reduce it.

 

"I am a woman and I am a world-class athlete. The IAAF (International Association of Athletics Federations) will not drug me or stop me from being who I am," Semenya, 28, said in a statement after filing the appeal on Wednesday.

South African Semenya lost an appeal to the Court of Arbitration for Sport (CAS) on May 1 which ruled the IAAF's regulations were necessary for athletes with differences in sexual development (DSDs) to ensure fair competition.

The statement added that Semenya will ask the Swiss Federal Supreme Court to set aside CAS's decision in its entirety, which it said did not consider medical protocols and uncertain health consequences of taking testosterone-reducing medication.

Get Rediff News in your Inbox:
Source: REUTERS
© Copyright 2024 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

India In Australia 2024-2025